Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative
and efficient diagnostics for better treatment decisions, today was informed
that the Oslo Stock Exchange has approved the company's application for transfer
of its shares to Oslo Børs from Euronext Growth. Reference is made to the
announcements 7 May 2021 regarding the application by Gentian for listing of its
shares on Oslo Børs.
"We made a promise to our shareholders when we were listed on Euronext Growth
that we would aim for the main list when the company had matured. I'm pleased
that we now have achieved this milestone, and that we have access to a
high-quality investor base as we work towards our ambitious targets of long-term
growth and value creation," says Hilja Ibert, CEO of Gentian Diagnostics.
In an updated investor presentation published 18 June 2021, the company outlined
the market potential and roadmap for its portfolio of high-impact diagnostic
tests. The long-term ambition is to generate an estimated annual revenue of NOK
1 billion in 5-7 years, up from NOK 79 million in 2020.
Gentian's portfolio of diagnostic tests contributes to early disease detection
and faster availability of clinically relevant information, which lead to better
treatment decisions. In addition, they contribute to improve laboratory
productivity and cost-efficiency by leveraging PETIA technology, which enable
3-10x higher throughput than traditional immunoassay platforms. The tests target
several large and growing disease areas such as infections and inflammation,
kidney failure and congestive heart failure. Gentian has four established
products, one product in market development, and two products in development
with launches scheduled for Q4 2021 and Q1 2022, respectively. Gentian also has
three undisclosed biomarkers in exploration and 'proof of concept' phases.
"We have a diversified portfolio of tests, providing a solid foundation for
growth and value creation. To deliver on our ambition, we aim to bring one
additional product to market per year and expand market access through achieving
additional regulatory approvals and commercial partners," says Ibert.
The company has the pleasure of inviting to a virtual presentation on Thursday
24 June 2021 at 10:00-11.00 am CEST. Gentian's CEO Hilja Ibert, CSO Erling
Sundrehagen and CFO Njaal Kind will present the company followed by a Q&A
session. Join the online presentation via the following link:
For further information, please contact:
Hilja Ibert, CEO
+47 919 05 242 (mobile)
Njaal Kind, CFO
+47 919 06 525 (mobile)
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit www.gentian.com.